Madrigal Pharmaceuticals Inc (MDGL)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$399.63

-0.47 (-0.12%)

Market Cap: $9.30B

Last updated: Nov 06, 2026 at 4:28 PM ET

Earnings

Performance (10Y)

Beat Rate

53%(21/40)

Avg Surprise

+1.42%

Streak

3 Q

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$0.97

Range$0.08 - $2.55

4 analysts

Revenue Consensus

$469M

Range$420M - $520M

18 analysts

Last 12 of 40 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.97	$0.08 - $2.55	-	-	4	-	-
Sep 30, 2026Sep 26 Reported Nov 3, 2026Reported Nov 3	$1.83	$-1.09	$-1.38 - $-0.56	+267.89%	Beat	4	No revisions (30d)	+136.9%
Jun 30, 2026Jun 26 Reported Jul 30, 2026Reported Jul 30	$-1.99	$-2.55	$-2.70 - $-2.35	+21.96%	Beat	3	0 1 30d	-4.7%
Mar 31, 2026Mar 26 Reported May 6, 2026Reported May 6	$-1.38	N/A	-	+66.67%	Beat	5	0 2 30d	+58.4%
Dec 31, 2025Dec 25 Reported Feb 19, 2026Reported Feb 19	$-2.57	$-0.60	$-4.42 - $1.36	-325.57%	Miss	7	0 2 30d	+5.2%
Sep 30, 2025Sep 25 Reported Nov 4, 2025Reported Nov 4	$-4.96	$-1.99	$-6.95 - $-0.66	-149.25%	Miss	14	2 0 30d	-0.8%
Jun 30, 2025Jun 25 Reported Aug 5, 2025Reported Aug 5	$-1.90	$-3.53	$-4.92 - $-2.25	+46.18%	Beat	13	2 0 30d	+73.2%
Mar 31, 2025Mar 25 Reported May 1, 2025Reported May 1	$-3.32	$-3.79	$-5.04 - $-2.71	+12.40%	Beat	13	0 1 30d	+55.0%
Dec 31, 2024Dec 24 Reported Feb 26, 2025Reported Feb 26	$-2.71	$-4.12	$-5.29 - $-3.44	+34.30%	Beat	14	4 1 30d	+52.3%
Sep 30, 2024Sep 24 Reported Oct 31, 2024Reported Oct 31	$-4.92	$-6.91	$-8.45 - $-6.28	+28.80%	Beat	15	4 0 30d	+7.9%
Jun 30, 2024Jun 24 Reported Aug 7, 2024Reported Aug 7	$-7.10	$-7.66	$-9.37 - $-6.52	+7.31%	Beat	15	1 0 30d	-51.4%
Mar 31, 2024Mar 24 Reported May 7, 2024Reported May 7	$-7.38	$-6.28	$-7.34 - $-4.86	-17.52%	Miss	13	No revisions (30d)	-74.5%
Dec 31, 2023Dec 23 Reported Feb 28, 2024Reported Feb 28	$-5.68	$-5.34	$-5.84 - $-4.58	-6.37%	Miss	12	No revisions (30d)	-14.1%

Key Metrics

Valuation
P/E Ratio	-97.23	EV/EBITDA	N/A
Price/FCF	-68.99x	FCF Yield	-1.45%
Profitability
Profit Margin	-10.90%	Operating Margin	13.00%
ROE	-24.80%	ROIC	-12.75%
Financial Health
Debt/Equity	0.54x	Interest Coverage	-4.86x
Current Ratio	3.05x	Quick Ratio	2.78x
Trading Statistics
Beta	-1.00	Avg Volume	541.94K
52-Week High	$615.00	52-Week Low	$353.54

Technical Indicators Dashboard

Moving Averages

SMA 10$419.88

SMA 20$437.39

SMA 50$486.74

SMA 200$497.60

EMA 10$417.63

EMA 20$436.35

EMA 50$469.83

EMA 200$488.19

MACD

Line: -23.77Signal: -21.21Hist: -2.56

ADX

ADX: 31.6+DI: 20.4-DI: 25.5

Aroon & PSAR

Aroon Up4.0

Aroon Down92.0

PSAR$477.61

Bollinger Bands

Upper Band$483.27

Lower Band$391.51

%B Position2098%(Upper)

Band Width0.09

RSI (14-Day)

Oversold

23.8

Momentum Oscillators

Stoch %K36.0

Stoch %D27.4

Williams %R-64.3

ROC (10d)-8.0%

Momentum-34.61

CCI (20d)-166.2

MFI (14d)29.1

Volatility Measures

ATR (14d)$23.52(5.9%)

StdDev (20d)22.94

Hist Vol40.4%(High)

Volume Flow

VWAP$393.17

OBV-362.4K

AD Line3.4M

CMF (20d)0.003

Volume Metrics

Avg Vol (20d)561.8K

Vol Ratio1.9x(High)

VWMA (20d)$420.80

Pivot Points

R3$434.22

R2$423.09

R1$411.59

Pivot Point$400.46

S1$388.96

S2$377.83

S3$366.33

Advanced Oscillators

TSI-46.77

Ultimate Osc42.7

KST-149.88

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$431.27M	$364.25M	$311.34M	$321.08M	$287.27M	$212.80M	$137.25M	$103.32M	$62.17M	$14.64M	$0	$770,000
Cost of Revenue	$0	$0	$0	$24.45M	$0	$0	$0	$3.44M	$0	$0	$0	$142,000
Gross Profit	$431.27M	$364.25M	$311.34M	$321.08M	$287.27M	$212.80M	$137.25M	$103.32M	$62.17M	$14.64M	$0	$-142,000

Operating Expenses	$375.28M	$420.56M	$404.06M	$380.69M	$401.24M	$260.00M	$216.56M	$170.32M	$178.48M	$177.18M	$152.04M	$117.18M
R&D	$71.75M	$91.18M	$108.69M	$116.27M	$174.00M	$54.08M	$44.17M	$25.65M	$68.74M	$71.09M	$71.24M	$70.64M
SG&A	$303.52M	$329.38M	$295.37M	$264.42M	$227.24M	$205.92M	$172.39M	$144.67M	$109.74M	$106.08M	$80.80M	$46.54M
Operating Income	$55.99M	$-56,308,000	$-92,723,000	$-59,609,000	$-113,975,000	$-47,202,000	$-79,311,000	$-66,997,000	$-116,304,000	$-162,537,000	$-152,037,000	$-117,176,000

Interest Income	$8.24M	$7.10M	$8.24M	$9.46M	$10.31M	$8.23M	$9.37M	$11.08M	$13.02M	$14.22M	$8.33M	$8.95M
Interest Expense	$8.07M	$7.94M	$7.82M	$8.30M	$10.23M	$3.26M	$3.30M	$3.50M	$3.68M	$3.66M	$3.84M	$3.97M
Income Before Tax	$55.44M	$-57,939,000	$-94,391,000	$-58,575,000	$-114,190,000	$-42,281,000	$-73,238,000	$-59,416,000	$-106,964,000	$-151,971,000	$-147,541,000	$-112,194,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$55.44M	$-57,939,000	$-94,391,000	$-58,575,000	$-114,190,000	$-42,281,000	$-73,238,000	$-59,416,000	$-106,964,000	$-151,971,000	$-147,541,000	$-112,194,000

EBITDA	$57.00M	$-55,613,000	$-93,572,000	$-57,201,000	$-112,030,000	$-46,441,000	$-78,440,000	$-66,094,000	$-115,984,000	$-161,798,000	$-151,214,000	$-116,281,000
EBIT	$55.27M	$-57,103,000	$-94,815,000	$-59,609,000	$-114,268,000	$-47,244,000	$-79,311,000	$-66,997,000	$-116,304,000	$-162,537,000	$-152,037,000	$-117,176,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about MDGL

Government Contracts

Gov Obligations (TTM)

$65309

Gov Obligations / Revenue

0.0%

Obligations YoY

N/A

Active Awards

New Awards (TTM)

Avg Remaining Term

N/A

Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

Recent Awards

Award ID	Agency	Obligated	Start	End	Description
36C24526N0482	Department of Veterans AffairsDepartment of Veterans Affairs	$35623	Apr 3, 2026	Apr 7, 2026	REZDIFFRA 80 MG
36C24526N0629	Department of Veterans AffairsDepartment of Veterans Affairs	$29686	Jun 5, 2026	Jun 12, 2026	REZDIFFRA 80 MG

Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

News

Madrigal’s MASH Drug Shows Improvements In Liver Health Across 4 Studies, Days After Company Disclosed $1.1B Rezdiffra Sales

Madrigal Pharmaceuticals reported encouraging real-world data for its MASH drug, Rezdiffra, showing significant improvements in liver stiffness across four studies...

Stocktwits•Nov 5, 2026 5:40 PM ET11/5/26•Bullish

MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL

Kirby McInerney LLP is investigating potential claims against Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) after a whistleblower complaint revealed allegations of suppressed adverse liver-injury data and unreproducible...

GlobeNewswire•Nov 4, 2026 6:11 PM ET11/4/26•Bearish

Madrigal Pharmaceuticals (MDGL) Stock May Be Below Fair Value Despite First Profit

Madrigal Pharmaceuticals (MDGL) has achieved profitability and its liver drug Rezdiffra has surpassed US$1 billion in annual sales...

Yahoo Finance UK•Nov 4, 2026 1:11 PM ET11/4/26•Somewhat-Bullish

Truist Securities maintains Madrigal Pharmaceuticals at Buy, raises price target to $743 from $709

Truist Securities has reiterated its "Buy" rating for Madrigal Pharmaceuticals and increased its price target to $743 from $709...

TradingView•Nov 4, 2026 12:11 PM ET11/4/26•Bullish

Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals reported robust financial results for Q3 2026, with net sales reaching $431 million, a 50% year-over-year increase, pushing year-to-date sales past $1 billion. Their MASH therapy, Rezdiffra...

Benzinga•Nov 3, 2026 10:40 PM ET11/3/26•Bullish

MDGL Valuation and Fair Value

P/E: -97.2x
Forward P/E: 57.1x
P/FCF: -69.0x
PEG: 0.0x
P/B: 18.6x

See GNG's fair value

MDGL Profitability: Margins, ROIC and FCF

Gross margin: 100.0%
Operating margin: 13.0%
Net margin: -10.9%
ROIC: -12.7%
ROE: -24.8%
FCF margin: -11.9%
FCF yield: -1.4%

MDGL Competitors

Company	Ticker
Hinge Health, Inc.	HNGE
Protagonist Therapeutics Inc	PTGX
Henry Schein Inc	HSIC
Krystal Biotech Inc	KRYS
Vaxcyte Inc	PCVX
Spyre Therapeutics Inc.	SYRE
Nuvalent Inc	NUVL
AptarGroup Inc	ATR

Sector: Healthcare

MDGL Analyst Ratings

Consensus: Buy
Analysts: 19
Strong Buy: 3
Buy: 15
Hold: 1
Sell: 0
Strong Sell: 0

MDGL Bull Case vs Bear Case

Bull case

MDGL beat EPS estimates in 75.0% of its last 8 reported quarters.
MDGL grew quarterly revenue 50.1% year over year.
94.7% of MDGL's analyst ratings are Buy or Strong Buy.

Bear case

MDGL has a -10.9% net profit margin.

MDGL Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: -3.2%
EPS estimate (fiscal period ending Dec 31, 2026): $0.97

MDGL Earnings Date

MDGL reports Feb 17, 2027, after the close. The date is estimated.

MDGL Earnings Call

The latest MDGL earnings call transcript on file is labeled 2026Q3.

Read the 2026Q3 transcript

MDGL ETF Holders

GNG tracks 13 ETFs that hold MDGL. The largest weights:

State Street SPDR S&P Biotech ETF (XBI), 1.13% of the fund
iShares Biotechnology ETF (IBB), 0.66% of the fund
Invesco NASDAQ Next Gen 100 ETF (QQQJ), 0.54% of the fund
Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.38% of the fund
Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.27% of the fund

Open the ETF Stock Exposure tool for MDGL

See insider activity

Frequently Asked Questions About MDGL

When does MDGL report earnings?

Madrigal Pharmaceuticals Inc (MDGL) is expected to report earnings on Feb 17, 2027.

Does MDGL pay dividends?

Madrigal Pharmaceuticals Inc (MDGL) does not currently pay a regular dividend.

What is MDGL's market cap?

Madrigal Pharmaceuticals Inc (MDGL) has a market capitalization of $9.30B with a current stock price of $399.63.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In